By Fineline Cube Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that China’s National Medical Products Administration (NMPA) has granted approval to initiate a clinical trial evaluating its investigational drug opamtistomig (LBL-024) for the treatment of metastatic colorectal cancer (mCRC).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial approval |
| Product | Opamtistomig (LBL-024) |
| Indication | Treatment of metastatic colorectal cancer (mCRC) |
| Approval Date | 3 Aug 2026 |
| Next Steps | Initiate Phase I/II clinical trial with dose escalation and safety evaluation |
Drug Profile & Mechanism of Action
- Molecule: Bispecific antibody therapeutic
- Target: PD-1/PD-L1 immunosuppressive pathway and 4-1BB co-stimulatory pathway
- Innovation: Simultaneously blocks PD-1/PD-L1 while conditionally activating 4-1BB, restoring T-cell function while promoting T-cell proliferation and long-term immune memory formation
- Clinical Validation: Activity demonstrated across multiple tumor types including extrapulmonary neuroendocrine carcinoma (EP-NEC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and biliary tract cancer (BTC)
Clinical Development Strategy
Leads Biolabs plans to initiate patient enrollment in the Phase I/II clinical trial within the next quarter, focusing initially on dose escalation and safety parameters before expanding to efficacy evaluation. The company has indicated potential for combination therapy approaches in subsequent development stages.
Colorectal cancer represents the second leading cause of cancer-related deaths in China, with metastatic forms presenting particularly poor prognosis and limited treatment options. This approval addresses a significant unmet medical need in one of China’s most prevalent and challenging cancer types.
Market Impact & Outlook
- China mCRC Landscape: With limited effective treatments for metastatic disease, novel immunotherapies with dual mechanisms represent high-value therapeutic assets
- Competitive Edge: Unlike single-target checkpoint inhibitors, opamtistomig’s dual mechanism may overcome resistance mechanisms seen with current immunotherapies
- Commercial Potential: The mCRC therapeutics market in China is projected to reach $2.3 billion by 2028, creating substantial opportunity for effective novel agents
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations for opamtistomig. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech